ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
2 files
0/0

Computer-Assisted Planning of Hydroxychloroquine’s Syntheses Commencing from Inexpensive Substrates and Bypassing Patented Routes.

preprint
submitted on 24.03.2020 and posted on 25.03.2020 by Sara Szymkuć, Ewa P. Gajewska, Karol Molga, Agnieszka Wołos, Rafał Roszak, Wiktor Beker, Martyna Moskal, Piotr Dittwald, Bartosz Grzybowski
A computer program for retrosynthetic planning helps develop multiple "synthetic contingency" plans for hydroxychloroquine, a promising but yet unproven medication against COVID-19. These plans are designed to navigate, as much as possible, around known and patented routes and to commence from inexpensive and diverse starting materials, such as to ensure supply in case of anticipated market shortages of the commonly used substrates.

Funding

69461-CH-DRP #W911NF1610384

IBS-R020-D1

#2014/12/W/ST5/00592

History

Email Address of Submitting Author

nanogrzybowski@gmail.com

Institution

Institute of Organic Chemistry, Polish Academy of Sciences

Country

Poland

ORCID For Submitting Author

0000-0001-6613-4261

Declaration of Conflict of Interest

The authors declare no financial interest in this work. While Chematica was originally developed and owned by B.A.G.’s Grzybowski Scientific Inventions, LLC, neither he nor the co-authors currently hold any stock in this company, which is now property of Merck KGaA, Darmstadt, Germany. Most of the authors have, until recently, collaborated with Merck KGaA, Darmstadt, on Chematica’s development within the DARPA “Make-It” award. All queries about access options to Chematica (now rebranded as SynthiaTM), including academic collaborations, should be directed to Dr. Sarah Trice at sarah.trice@sial.com.

Licence

Exports